TriSalus Life Sciences Appoints New CMO, Director
Ticker: TLSIW · Form: 8-K · Filed: Feb 25, 2025 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Feb 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment
TL;DR
TriSalus Life Sciences beefs up exec team with new CMO and adds a director to the board.
AI Summary
TriSalus Life Sciences, Inc. announced on February 19, 2025, the appointment of Dr. David L. Smith as Chief Medical Officer and the election of Ms. Jennifer L. Johnson to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are provided in the filing.
Why It Matters
These executive and board changes at TriSalus Life Sciences could signal strategic shifts in the company's medical and governance direction.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — Registrant
- Dr. David L. Smith (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Johnson (person) — Elected to Board of Directors
- February 19, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. David L. Smith has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Jennifer L. Johnson has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 19, 2025.
What is the principal executive office address for TriSalus Life Sciences, Inc.?
The principal executive office address is 6272 W 91st Ave, Westminster, Colorado 80031.
What is the telephone number for TriSalus Life Sciences, Inc.?
The telephone number is (888) 321-5212.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 25, 2025 by Dr. David L. Smith regarding TriSalus Life Sciences, Inc. (TLSIW).